Evotec and C4XD Enter Collaboration to Identify Pre-Clinical Development Candidates for Stress-Related Addictive Disorder Pro...
19 January 2015 - 5:38PM
- Collaboration leverages the breadth & experience of
Evotec's drug discovery infrastructure across chemistry &
biology
- Efforts will combine the use of C4XD's
proprietary NMR technology to conformational ligand design
with Evotec's state-of-the-art biology & computational and
medicinal chemistry capabilities
Evotec AG (Frankfurt Stock Exchange:EVT) (TecDAX)
(ISIN:DE0005664809) today announced a research collaboration with
C4X Discovery Holdings plc ("C4XD") to optimise Orexin-1 selective
inhibitors discovered through C4XD's unique NMR technology. Evotec
will apply its drug discovery platform with C4XD to further develop
several series of Orexin-1 selective inhibitors.
Activation of the orexin-1 receptor in the brain is associated
with stress-related addictive disorders (e.g. for alcohol,
nicotine, cocaine and opiates), while the activation of the
orexin-2 receptor is associated with biorhythms and wakefulness.
Identification and development of selective compounds that inhibit
the orexin-1 pathway thus should provide treatments for addiction
avoiding the sedative effects associated with inhibition of
orexin-2.
"We are delighted to work with C4XD on this strategic
collaboration. C4XD has an exciting technology that can really
revolutionise how rational drug design is conducted, particularly
on targets like Orexin where the conformation of drug-like ligands
is particular important to on-target potency. With Evotec's
complementary expertise in computational chemistry, medicinal
chemistry and pharmacology we look forward to help drive C4XD's
objective to develop compounds to treat addictive disorders,"
said Dr Mario Polywka, Chief Operating
Officer of Evotec.
"Through this collaboration with Evotec, we expect our novel
biological discoveries and medical insights will be effectively and
efficiently progressed into a state-of-the-art drug discovery and
development programme. The collaboration is already demonstrating
the benefit of an alliance in accelerating drug discovery
projects," said Piers Morgan, CEO of
C4XD.
No financial details were disclosed.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership
company focused on rapidly progressing innovative product
approaches with leading pharmaceutical and biotechnology companies.
We operate worldwide providing the highest quality stand-alone and
integrated drug discovery solutions, covering all activities from
target-to-clinic. The Company has established a unique position by
assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology, inflammation and infectious
diseases. Evotec has long-term discovery alliances with partners
including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition,
the Company has existing development partnerships and product
candidates both in clinical and pre-clinical development. These
include partnerships with Boehringer Ingelheim and MedImmune in the
field of diabetes, with Janssen Pharmaceuticals in the field of
depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.
ABOUT C4X DISCOVERY HOLDINGS PLC
C4XD is a Manchester-based company focused on optimising drug
discovery and design. It was founded in 2008 as a spin-out from the
University of Manchester. The company uses its NMR-based technology
to solve the dynamic 3D structures of a broad range of
biomolecules, including peptides, cofactors, oligonucleotides and
carbohydrates. Since C4XD's NMR technology shows what shapes active
molecules prefer to adopt, it provides high-quality templates for
drug discovery and design, and valuable information for drug
candidate optimisation. In addition, the data is generated faster
and more reliably than standard techniques such as X-ray
co-crystallography or molecular modelling. C4XD is using its
technology in collaboration with the pharmaceutical industry and to
build its own proprietary pipeline of high-value therapeutic
candidates. www.c4xdiscovery.com
FORWARD LOOKING STATEMENTS — Information set
forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement
of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to
a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. We
expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions
or circumstances on which any such statement is based.
CONTACT: For further information, please contact
Gabriele Hansen
VP, Corporate Communications & Investor Relations
+49.(0)40.560 81-255
+49.(0)40.560 81-333 Fax
gabriele.hansen@evotec.com
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jul 2023 to Jul 2024